CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
Portfolio Pulse from Vandana Singh
CymaBay Therapeutics Inc (NASDAQ:CBAY) announced positive topline results from its Phase 3 RESPONSE study of seladelpar for adult patients with primary biliary cholangitis (PBC). The trial achieved the primary and all key secondary endpoints, supporting advancement to regulatory discussions and filing for regulatory approval with the FDA, the UK Medicines and Healthcare Products Regulatory Agency, and the European Medicines Agency. The company's shares are up 7.16% at $14.80 on the last check Thursday.
September 07, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics' lead drug seladelpar achieved its main goal in a Phase 3 study for liver damage, leading to a 7.16% increase in the company's stock price.
The positive results from the Phase 3 study of seladelpar, CymaBay Therapeutics' lead drug, are a significant milestone for the company. This news is likely to boost investor confidence in the company's ability to bring the drug to market, which is reflected in the 7.16% increase in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100